Ofichem Group Acquires Avivia to Expand Complex Formulation Development Capabilities
核心洞察
Ofichem Group (搜索) has agreed to acquire Avivia B.V. (搜索), a Netherlands-based contract development organization specializing in formulation development and analytical method development.
The acquisition strengthens Ofichem's integrated development offering, enabling broader support from early-phase development through GMP production with enhanced complex formulation capabilities.
Avivia brings a team of 10 scientists with expertise in dissolution profiling, excipient characterization, and stability testing to complement Ofichem's operations in Ter Apel and Leiden.
Ofichem Group (搜索) has agreed to acquire Avivia B.V. (搜索), a Netherlands-based contract development organization specializing in formulation development, marking a significant expansion of the European CDMO's complex drug development capabilities. The acquisition of the Nijmegen-based company represents a strategic step in Ofichem's evolution toward becoming a fully integrated provider of development solutions across drug substance and drug product development.
Strategic Expansion of Development Services
Avivia operates as a contract development organization with specialized expertise in formulation development, analytical method development, dissolution testing, and excipient characterization. The acquisition will enable Ofichem to offer broader, deeper support from early-phase development through to GMP production, with particular strength in complex formulations.
"By integrating Avivia into the Ofichem Group (搜索), we are strengthening our ability to support customers from drug substance through R&D and small to large scale GMP manufacturing and reinforcing our commitment to innovation and customer-centricity," said Dr. Weite H. Oldenziel (搜索), CEO and owner of the Ofichem Group.
Enhanced Scientific Capabilities
The acquisition brings a team of 10 scientists with extensive experience in dissolution profiling, excipient characterization, and stability testing. These capabilities will complement Ofichem's current operations in Ter Apel and Leiden, strengthening the company's reach in Europe and North America.
Avivia's focus on preformulation, formulation, and analytical method development for complex drug products aligns with Ofichem's strategic direction. The specialized expertise in complex formulations addresses growing industry demand for sophisticated drug development solutions.
Science-Led CDMO Evolution
"This acquisition enhances our ability to provide integrated, complex drug development services from early-phase to commercial scale," Oldenziel stated. "This move further supports our ambition to evolve as a science-led CDMO and deliver innovation-driven solutions to our customers with enhanced capability in solving complex formulation challenges."
The integration of Avivia's talented team into the Ofichem Group (搜索) is expected to strengthen the company's innovation-driven approach to pharmaceutical development. The acquisition complements Ofichem's existing capabilities and enables the delivery of more comprehensive services to global customers seeking end-to-end development solutions from drug substance development through GMP manufacturing.